The content on this site is intended for healthcare professionals only
Dr Gay speaks with ecancer at EHA 2018 about updated data from the FORTE trial, looking at newly diagnosed myeloma patients treated with carfilzomib plus lenalidomide or cyclophosphamide.
She states that one of the primary objectives of the trail was response rate after the induction phase and both regiments of patients were highly effective with roughly 90% of patients in both arms achieving a partial response.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer
Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
OncoAlert Round Up for September 15-21, 2023
The Southeast Asian Breast Cancer Symposium; background, aims and successes
OncoAlert Round Up for August 25th - 31st, 2023
OncoAlert Round Up for August 11th - 17th, 2023
Latest in immunological technologies that can treat, control, and prevent cancer
OncoAlert Round Up for August 4th - 10th, 2023
